Trevi Therapeutics GAAP EPS of -$0.12 misses by $0.01

Nov. 10, 2022 4:18 PM ETTrevi Therapeutics, Inc. (TRVI)By: Urvi Shah, SA News Editor
  • Trevi Therapeutics press release (NASDAQ:TRVI): Q3 GAAP EPS of -$0.12 misses by $0.01.
  • Cash and cash equivalents of $66.57M
  • Net loss: For the third quarter of 2022, the Company reported a net loss of $8.3 million, compared to a net loss of $7.3 million in the same period in 2021. The increase was primarily due to the increase in R&D expenses.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.